



Start **Seeing Wounds**  
In A **New Light**™



# Transform Your Practice

## DETECT Bacterial Loads

Uncover bacterial hotspots  
that delay healing<sup>1</sup>

## MEASURE Wounds Digitally

Fast, accurate & stickerless  
with wound area tracking<sup>2</sup>



## INFORM Treatment

For more effective bacterial-  
infection management<sup>3</sup>

## IMPROVE Outcomes

RCT evidence shows twice as many  
wounds healed with MolecuLight<sup>4</sup>


Innovative & field-leading technology  
for bedside bacterial wound imaging

<sup>1</sup>Rennie et al. *Diagnostics* 2019; <sup>2</sup>Raizman et al. *J Wound Care* 2019;  
<sup>3</sup>Jacob et al. *Int Wound J* 2023; <sup>4</sup>Rahma et al. *Diabetes Care* 2022



## How the MolecuLightDX™ Works

The device emits a safe, **violet light**, which causes regions of high bacterial loads (>10<sup>4</sup> CFU/g) to produce detectable fluorescence colors<sup>1</sup>.




**Red fluorescence**  
most bacterial species

**Green fluorescence**  
Tissue components for anatomical context

**Cyan fluorescence**  
*Pseudomonas aeruginosa*


### Diabetic Foot Ulcers



Standard image

Fluorescence image

### Venous Leg Ulcers



Standard image

Fluorescence image

## You Can't Treat What You Can't See

Accumulation of harmful bacteria delays healing and increases the risk of infection<sup>2,3</sup>.

**MolecuLightDX enables you to quickly detect high bacterial loads and manage them early**, with any wound type in any care setting.

Safe

Non-contact

No contrast agents

Real-time imaging

<sup>1</sup>Le et al. (2021) *Adv Wound Care*; <sup>2</sup>Armstrong et al. (2023) *Int Wound J*; <sup>3</sup>Rippon et al. (2022) *J Wound Care*

## Improve Patient Throughput & Streamline Documentation

Replace inefficient manual workflows with an **all-in-one digital measurement solution**:

- Minimize variability between providers
- Automatically graph wound area over time
- Quickly review wound area changes at the bedside
- Use on every wound at every visit

Stickerless

>95% Accurate



Streamlined Workflow

Auto-depth\*


## Multi-Functional Solution to Enhance Assessment

With **one set of gloves and a few clicks**, get accurate, organized measurements to identify healing delays early.

Then, use fluorescence imaging to determine if bacteria/infection is an underlying cause for the healing delay.

\*Auto-depth feature coming soon





The **DX** provides clinicians with objective, real-time information on high bacterial loads and their location to **enhance bacterial-infection management**.

**69%** of treatment plans changed after MolecuLight imaging<sup>5</sup>



...Bacterial infection is the greatest destroyer of the diabetic foot. It is the final common pathway for most amputations, and we need to fight it as early as possible. We've demonstrated that chronic inhibitory bacterial loads can delay healing in diabetic foot ulcers which often do not present with infective symptoms<sup>6</sup>.  
**The MolecuLight device empowers us to proactively address and better treat these bacterial loads, before infection escalates to serious complications.**

**Michael E. Edmonds, MD FRCP**  
Honourary Professor and Founder, Diabetic Foot Clinic  
King's College Hospital Foundation Trust, London, UK

<sup>1</sup>Jacob A et al. (2023) *Int Wound J*; <sup>2</sup>Raizman R et al. (2019) *J Wound Care*; <sup>3</sup>Price N (2020) *Diagnostics*; <sup>4</sup>Ai-Jalodi O et al. (2021) *J Wound Care*; <sup>5</sup>Le L et al. (2021) *Adv Wound Care*; <sup>6</sup>Armstrong et al. (2023) *Int Wound J*



## Improved Wound Healing Rates

Twice as many wounds healed at 12-weeks for patients receiving MolecuLight imaging in an independent, randomized control trial (RCT) of 56 diabetic foot ulcers<sup>1</sup>.

2X

IMPROVED 12-WEEK  
HEALING RATE  
(IN RCT)

View RCT Results  
featuring MolecuLight



## Extensive Body of Clinical Evidence

MolecuLight is validated by an **extensive body of clinical trials and peer-reviewed publications from around the world** illustrating the benefits of the technology to support clinical decision-making.

80+

PEER-REVIEWED  
PUBLICATIONS

2,600+

PATIENTS IN CLINICAL  
STUDIES

Download  
Listing of Publications  
featuring MolecuLight



**Martha R. Kelso, RN, HBOT**

Chief Executive Officer,  
Wound Care Plus, LLC

<sup>1</sup>Rahma, S. et al. (2022) *Diabetes Care*; <sup>2</sup>Kelso M., *WoundCon Summer 2022*

MolecuLight's revolutionary technology has transformed our treatment approach to complex, hard-to-heal wounds by **improving wound healing rates, reducing systemic antibiotic usage (↓29%), and decreasing severe infection-related complications 5-fold<sup>2</sup>**. It has quickly become our secret weapon in the fight against covert infections in our highly vulnerable LTC/SNF patient population.

## Empowering Patients & Encouraging Compliance

Engaged patients **show up for their visits** and actively participate in their care. The use of MolecuLight helps to empower and engage your patients.

93%

of patients reported that MolecuLight led to a **greater sense of hope, lessened anxiety, and greater trust in their wound care provider<sup>1</sup>**.

76%

of patients said they were **more likely to carry out at-home care plans and return for future appointments** when MolecuLight was used during their wound care visits<sup>1</sup>.



**Rosemary Hill, BSN CWOCN**

Vancouver Coastal Health,  
Vancouver, BC Canada

<sup>1</sup>Andersen C.A., SAWC [poster] 2023

When our team adopted MolecuLight we discovered that **we cannot make assumptions about where bacterial loads are in the wound -- and where they are not**. It was striking to see the predominance of bacteria, particularly *Pseudomonas*, not just in the wound bed but even more so in the periwound. These bacteria must be addressed through vigorous and targeted wound hygiene.

Pressure Injury & Periwound Tissue



Red fluorescence indicates presence of elevated bacterial burden (>10<sup>4</sup> CFU/g) throughout the periwound in this sacral pressure injury.

MolecuLight technology leads to **substantial cost savings**:

### Faster time to heal<sup>1</sup>

Wound duration is the largest driver of wound care costs<sup>2</sup>

### Fewer infection complications<sup>3</sup>

Infected wounds cost up to 10x more to treat<sup>4</sup>

**Projected annual savings of 10%** can be achieved through faster healing and reduced healthcare costs by utilizing MolecuLight regularly<sup>5</sup>.



**Nadine Price,**  
MSc, BSc (Hons) Podiatry  
NELFT, National Health Service (NHS)  
London, UK

**MolecuLight has been transformative for our patients and practices within the NHS.** We improved our wound healing rates, provided care in a more cost efficient manner, and were able to treat 27% more patients the year after we started using MolecuLight<sup>3</sup>. **We saw definitive cost savings in our product usage, including more rational use of systemic antibiotics, and estimate that our healing rate improvements decreased our annual wound care costs by 10%<sup>5</sup>.** This innovative technology is practice-altering and has enhanced the standard of care at NHS facilities.

<sup>1</sup>Rahma, S. et al. (2022) *Diabetes Care*; <sup>2</sup>Butcher M. (2014) *Nursing Standard*; <sup>3</sup>Kelso M., WoundCon Summer 2022; <sup>4</sup>Nussbaum S.R. (2018) *Value In Health*; <sup>5</sup>Price N. (2020) *Diagnostics*


Watch the  
Webcast



**Kylie Sandy-Hodgetts,**  
BSc MBA PhD

Associate Professor, Murdoch University  
Director Skin Integrity Research Institute (SKINRI)  
President, International Surgical Wound  
Complications Advisory Panel

Clinicians need an **objective means of detecting infection or another surgical wound complication** that will provide visual loci and confirmation of pathogen presence in conjunction with standard clinical assessment. **Fluorescence imaging using MolecuLight is positioned to change contemporary paradigms of post-surgical wound management** due to its ability to quickly and reliably detect bacterial burden and visualize contamination at the point-of-care.



### Surgical Site Infections (SSI)



Red fluorescence (right) indicates presence and location of elevated bacterial burden (>10<sup>4</sup> CFU/g) in this surgical site infection.

## Support from Expert Clinicians

Our experienced applications team will connect with you **remotely** for:

- DX setup and device use-training
- Image interpretation training
- Optimal integration into your workflow



**Ongoing support** to answer questions regarding connectivity, and device troubleshooting







**Dr. Jonathan Johnson,**  
**MD MBA, WCSP, FAPWCA**  
Founder/Surgical Director,  
Comprehensive Wound Care  
Services and Capital Aesthetic &  
Laser Center, Washington, DC, USA



**MolecuLight is a non-negotiable for our practice.** It has the ability to detect covert infections early in all skin tones, especially darker skin tone patients whose infections are usually detected too late. **MolecuLight is revolutionary for global wound care by helping reduce mistreatment and complications.**



Watch the **Webcast**



Interested in **more information** on the MolecuLightDX,  
**booking a demonstration** or **requesting a quote**?

Call **+1 647-362-4684**, email [info@moleculight.com](mailto:info@moleculight.com) or visit [www.moleculight.com](http://www.moleculight.com)



Health  
Canada

MolecuLightDX is in strict  
conformance with Data, Medical  
Device & Cyber Security Standards



[www.moleculight.com](http://www.moleculight.com)

The MolecuLightDX™ Imaging Device is approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.  
The MolecuLightDX™ Imaging Device has received FDA clearance.  
MolecuLight®, MolecuLightDX™, and *Start Seeing Wounds in a New Light™* are registered trademarks of MolecuLight Inc.  
©2023 MolecuLight Inc. All Rights Reserved. MKT-2346 Rev 2.0

For global distribution outside of the USA



MolecuLight®